Cannabinoid treatment for children with hard-to-treat cancers
Part of Cancer, Mental health clinical trials.
This early-phase study tests whether a cannabinoid medicine (including nabilone/cannabis-based treatment) can be given safely to children and teens with relapsed or refractory cancer. It may help with treatment options for children whose cancer has come back or did not respond to standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 4 and 17 years old at enrollment.
- Have a solid tumor or blood cancer that has come back (relapsed) or is not responding (refractory), including brain tumors.
- Be getting active cancer treatment or supportive/palliative care right now.
- Have an expected survival of at least 4 months.
- Be able to stop cannabis/nabilone use for the past 2 weeks and not use it during the study (or be willing to follow this rule).
- Not have major heart problems, very poor liver/kidney function, unstable heart rhythm, uncontrolled high blood pressure, or recent heart attack.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial helps children, teens, and young adults get an innovative cancer medicine when their disease has returned or hasn’t responded—and standard options are not available. It checks whether a “compassionate use” or off-label medicine plan can be carried out safely for the people who need it.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
Hear when a new Childhood Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.